mProX™ Human CDK3 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1068	Magic™ Human CDK3/CycE1 in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

CDK3

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

MCF7; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Cancer Research; Ocular Research

Related Diseases

Retinoblastoma. Among its related pathways are Activation of the pre-replicative complex and GADD45 Pathway

Gene ID

1018

UniProt ID

Q00526

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Prior to the actions of CDK4/cyclin D, CDK6/cyclin D, and CDK2/cyclin E, cyclin-dependent kinase 3 (CDK3) is a significant factor promoting retinoblastoma (Rb) phosphorylation during the G0/G1 transition and in the early G1 phase of the cell cycle. By eschewing Rb's function in late G1, CDK3 can also directly control the activity of E2 factor (E2F), possibly through phosphorylating E2F1 partner DP1. Extending beyond the cell cycle, CDK3 engages in interactions with many transcription factors that are implicated in the proliferation, differentiation, and transformation of cells, which are mediated by the rat sarcoma virus (Ras)/EGFR signaling pathway. Although CDK3 expression is incredibly low in healthy human tissue, it is increased in numerous malignancies, suggesting that CDK3 plays a significant role in oncogenesis. The customized CDK3 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Melissa

Reliable and repeatable throughout the CDK3 cell line use. Sep 02 2023

chat Verified Customer

chat Timothy

I highly recommend the CDK3 cell line for anyone working on membrane protein research. Apr 25 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 CDK3 is highly expressed in non-malignant breast cancer.

Western blotting revealed the presence of CDK3 expression in the malignant breast cancer cell lines MDA-MB-231 and BT549 as well as the non-malignant breast cancer cell lines MCF7, T47D. A loading control was applied using β-Actin.

Ref: Cao, Ting, et al. "CDK3, target of miR-4469, suppresses breast cancer metastasis via inhibiting Wnt/β-catenin pathway." Oncotarget 8.49 (2017): 84917.

Pubmed: 29156693

DOI: 10.18632/oncotarget.18171

Research Highlights

These findings demonstrated the critical role played by the Cdk3/c-Jun signaling axis in mediating the epithelial-mesenchymal transition in colorectal cancer metastasis.
Lu, Jinping, et al. "Cdk3-promoted epithelial-mesenchymal transition through activating AP-1 is involved in colorectal cancer metastasis." Oncotarget 7.6 (2016): 7012.
Pubmed: 26755651 DOI: 10.18632/oncotarget.6875

Although CDK3 expression is incredibly low in healthy human tissue, it is increased in numerous malignancies, suggesting that CDK3 plays a significant role in oncogenesis. The absence of specific pharmacological inhibitors has complicated further investigation of this function.
Teo, Theodosia, et al. "An overview of CDK3 in cancer: clinical significance and pharmacological implications." Pharmacological Research 180 (2022): 106249.
Pubmed: 35533805 DOI: 10.1016/j.phrs.2022.106249